k 2023

Quality control of clinical-grade human embryonic stem cells

SOURALOVÁ, Tereza, Pavel VENTRUBA, Michal JEŠETA, Daniela ŘEHÁKOVÁ, Aleš HAMPL et. al.

Basic information

Original name

Quality control of clinical-grade human embryonic stem cells

Authors

SOURALOVÁ, Tereza (203 Czech Republic, belonging to the institution), Pavel VENTRUBA (203 Czech Republic, belonging to the institution), Michal JEŠETA (203 Czech Republic, belonging to the institution), Daniela ŘEHÁKOVÁ (203 Czech Republic, belonging to the institution), Aleš HAMPL (203 Czech Republic, belonging to the institution) and Irena KOUTNÁ (203 Czech Republic, belonging to the institution)

Edition

Standardizing Stem Cell Core Facilities in Europe: a CorEuStem Symposium, Lisbon, Portugal, 2023

Other information

Language

English

Type of outcome

Prezentace na konferencích

Field of Study

10605 Developmental biology

Country of publisher

Portugal

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/23:00134631

Organization unit

Faculty of Medicine

Keywords in English

human embryonic stem cells; quality control

Tags

International impact
Změněno: 22/4/2024 14:30, Mgr. Tereza Miškechová

Abstract

V originále

Human embryonic stem cells are able to differentiate into every cell type in the human body making them a tremendous cell source for regenerative medicine. However, the production of human embryonic stem cell lines for clinical use is challenging as clean rooms, highly-qualified personnel, and standard operating procedures for both manufacture and quality control are required. Here we present the quality control of clinical-grade hESC lines that were derived in xeno-free, feeder-free conditions, and according to current good manufacturing practices. In-depth quality control provides essential information about the safety, pluripotency, and differentiation potential of lines and it is a necessary component of new clinical-grade hESC line establishment.

Links

CZ.02.1.01/0.0/0.0/16_013/0001826, interní kód MU
(CEP code: EF16_013/0001826)
Name: CZECRIN_PRO PACIENTY - zavádění inovativních moderních terapií
Investor: Ministry of Education, Youth and Sports of the CR, Priority axis 1: Strengthening capacities for high-quality research
NU22-08-00629, research and development project
Name: Vývoj postupů pro léčbu makulární degenerace sítnice deriváty lidských pluripotentních kmenových buněk
Investor: Ministry of Health of the CR, Subprogram 1 - standard